Phase 2 Trial of Brigatinib After Treatment With Second-Generation ALK Inhibitors in Refractory ALK Rearranged Non-Small Cell Lung Cancer (NSCLC)
Phase of Trial: Phase II
Latest Information Update: 06 Apr 2017
At a glance
- Drugs Brigatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 10 Mar 2017 Status changed from not yet recruiting to recruiting.
- 20 Oct 2016 Planned initiation date changed from 1 Jun 2016 to 1 Nov 2016.
- 09 May 2016 Planned End Date changed from 1 Mar 2019 to 1 Jun 2019.